Diederik W D Kuster1,2, Thomas L Lynch1, David Y Barefield1,3, Mayandi Sivaguru4, Gina Kuffel5, Michael J Zilliox5, Kyoung Hwan Lee6, Roger Craig6, Rajasekaran Namakkal-Soorappan7, Sakthivel Sadayappan1,8. 1. Cell and Molecular Physiology, Loyola University Chicago, Maywood, IL, USA. 2. Department of Physiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, Netherlands. 3. Center for Genetic Medicine, Northwestern University, Chicago, IL, USA. 4. Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Champaign, IL, USA. 5. Public Health Sciences, Loyola University Chicago, Maywood, IL, USA. 6. Division of Cell Biology and Imaging, Department of Radiology, University of Massachusetts Medical School, Worcester, MA, USA. 7. Molecular and Cellular Pathology, Department of Pathology, School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA. 8. Heart, Lung and Vascular Institute, Division of Cardiovascular Health and Disease, Department of Internal Medicine, University of Cincinnati, 231 Albert Sabin Way, Cincinnati, OH, USA.
Abstract
AIMS: A 25-base pair deletion in the cardiac myosin binding protein-C (cMyBP-C) gene (MYBPC3), proposed to skip exon 33, modifies the C10 domain (cMyBP-CΔC10mut) and is associated with hypertrophic cardiomyopathy (HCM) and heart failure, affecting approximately 100 million South Asians. However, the molecular mechanisms underlying the pathogenicity of cMyBP-CΔC10mutin vivo are unknown. We hypothesized that expression of cMyBP-CΔC10mut exerts a poison polypeptide effect leading to improper assembly of cardiac sarcomeres and the development of HCM. METHODS AND RESULTS: To determine whether expression of cMyBP-CΔC10mut is sufficient to cause HCM and contractile dysfunction in vivo, we generated transgenic (TG) mice having cardiac-specific protein expression of cMyBP-CΔC10mut at approximately half the level of endogenous cMyBP-C. At 12 weeks of age, significant hypertrophy was observed in TG mice expressing cMyBP-CΔC10mut (heart weight/body weight ratio: 4.43 ± 0.11 mg/g non-transgenic (NTG) vs. 5.34 ± 0.25 mg/g cMyBP-CΔC10mut, P < 0.05). Furthermore, haematoxylin and eosin, Masson's trichrome staining, as well as second-harmonic generation imaging revealed the presence of significant fibrosis and a greater relative nuclear area in cMyBP-CΔC10mut hearts compared with NTG controls. M-mode echocardiography analysis revealed hypercontractile hearts (EF: 53.4%±2.9% NTG vs. 66.4% ± 4.7% cMyBP-CΔC10mut; P < 0.05) and early diastolic dysfunction (E/E': 28.7 ± 3.7 NTG vs. 46.3 ± 8.4 cMyBP-CΔC10mut; P < 0.05), indicating the presence of an HCM phenotype. To assess whether these changes manifested at the myofilament level, contractile function of single skinned cardiomyocytes was measured. Preserved maximum force generation and increased Ca2+-sensitivity of force generation were observed in cardiomyocytes from cMyBP-CΔC10mut mice compared with NTG controls (EC50: 3.6 ± 0.02 µM NTG vs. 2.90 ± 0.01 µM cMyBP-CΔC10mut; P < 0.0001). CONCLUSION: Expression of cMyBP-C protein with a modified C10 domain is sufficient to cause contractile dysfunction and HCM in vivo. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: A 25-base pair deletion in the cardiac myosin binding protein-C (cMyBP-C) gene (MYBPC3), proposed to skip exon 33, modifies the C10 domain (cMyBP-CΔC10mut) and is associated with hypertrophic cardiomyopathy (HCM) and heart failure, affecting approximately 100 million South Asians. However, the molecular mechanisms underlying the pathogenicity of cMyBP-CΔC10mutin vivo are unknown. We hypothesized that expression of cMyBP-CΔC10mut exerts a poison polypeptide effect leading to improper assembly of cardiac sarcomeres and the development of HCM. METHODS AND RESULTS: To determine whether expression of cMyBP-CΔC10mut is sufficient to cause HCM and contractile dysfunction in vivo, we generated transgenic (TG) mice having cardiac-specific protein expression of cMyBP-CΔC10mut at approximately half the level of endogenous cMyBP-C. At 12 weeks of age, significant hypertrophy was observed in TG mice expressing cMyBP-CΔC10mut (heart weight/body weight ratio: 4.43 ± 0.11 mg/g non-transgenic (NTG) vs. 5.34 ± 0.25 mg/g cMyBP-CΔC10mut, P < 0.05). Furthermore, haematoxylin and eosin, Masson's trichrome staining, as well as second-harmonic generation imaging revealed the presence of significant fibrosis and a greater relative nuclear area in cMyBP-CΔC10mut hearts compared with NTG controls. M-mode echocardiography analysis revealed hypercontractile hearts (EF: 53.4%±2.9% NTG vs. 66.4% ± 4.7% cMyBP-CΔC10mut; P < 0.05) and early diastolic dysfunction (E/E': 28.7 ± 3.7 NTG vs. 46.3 ± 8.4 cMyBP-CΔC10mut; P < 0.05), indicating the presence of an HCM phenotype. To assess whether these changes manifested at the myofilament level, contractile function of single skinned cardiomyocytes was measured. Preserved maximum force generation and increased Ca2+-sensitivity of force generation were observed in cardiomyocytes from cMyBP-CΔC10mut mice compared with NTG controls (EC50: 3.6 ± 0.02 µM NTG vs. 2.90 ± 0.01 µM cMyBP-CΔC10mut; P < 0.0001). CONCLUSION: Expression of cMyBP-C protein with a modified C10 domain is sufficient to cause contractile dysfunction and HCM in vivo. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Berglind Adalsteinsdottir; Polakit Teekakirikul; Barry J Maron; Michael A Burke; Daniel F Gudbjartsson; Hilma Holm; Kari Stefansson; Steven R DePalma; Erica Mazaika; Barbara McDonough; Ragnar Danielsen; Jonathan G Seidman; Christine E Seidman; Gunnar T Gunnarsson Journal: Circulation Date: 2014-07-30 Impact factor: 29.690
Authors: J A Moolman; S Reith; K Uhl; S Bailey; M Gautel; B Jeschke; C Fischer; J Ochs; W J McKenna; H Klues; H P Vosberg Journal: Circulation Date: 2000-03-28 Impact factor: 29.690
Authors: Tatum S Simonson; Yuhua Zhang; Chad D Huff; Jinchuan Xing; W Scott Watkins; David J Witherspoon; Scott R Woodward; Lynn B Jorde Journal: Ann Hum Genet Date: 2010-02-18 Impact factor: 1.670
Authors: H Watkins; D Conner; L Thierfelder; J A Jarcho; C MacRae; W J McKenna; B J Maron; J G Seidman; C E Seidman Journal: Nat Genet Date: 1995-12 Impact factor: 38.330
Authors: Thomas L Lynch; Mohit Kumar; James W McNamara; Diederik W D Kuster; Mayandi Sivaguru; Rohit R Singh; Michael J Previs; Kyoung Hwan Lee; Gina Kuffel; Michael J Zilliox; Brian Leei Lin; Weikang Ma; Aaron M Gibson; Burns C Blaxall; Michelle L Nieman; John N Lorenz; Dana M Leichter; Owen P Leary; Paul M L Janssen; Pieter P de Tombe; Richard J Gilbert; Roger Craig; Thomas Irving; David M Warshaw; Sakthivel Sadayappan Journal: J Mol Cell Cardiol Date: 2021-03-26 Impact factor: 5.763
Authors: Sholeh Bazrafshan; Robert Sibilia; Saavia Girgla; Shiv Kumar Viswanathan; Megan J Puckelwartz; Kiranpal S Sangha; Rohit R Singh; Mashhood Kakroo; Roman Jandarov; David M Harris; Jack Rubinstein; Richard C Becker; Elizabeth M McNally; Sakthivel Sadayappan Journal: Front Cardiovasc Med Date: 2021-12-23